Id: acc0002
Group: 1sens
Protein: Ku70
Gene Symbol: XRCC6
Protein Id: P12956
Protein Name: XRCC6_HUMAN
PTM: acetylation
Site: unclear
Site Sequence:
Disease Category: Cancer
Disease: Lung Cancer
Disease Subtype: NSCLC
Disease Cellline: H358
Disease Info:
Drug: gefitinib + Vorinostat
Drug Info: Gefitinib is a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR-sensitive mutations. Vorinostat: -
Effect: promote
Effect Info: Amphiregulin promotes the resistance of non - small cell lung cancer cells to gefitinib by down - regulating the acetylation of Ku70.
Note:
Score: 5.0
Pubmed(PMID): 19826407
Sentence Index:
Sentence:

Sequence & Structure:

MSGWESYYKTEGDEEAEEEQEENLEASGDYKYSGRDSLIFLVDASKAMFESQSEDELTPFDMSIQCIQSVYISKIISSDRDLLAVVFYGTEKDKNSVNFKNIYVLQELDNPGAKRILELDQFKGQQGQKRFQDMMGHGSDYSLSEVLWVCANLFSDVQFKMSHKRIMLFTNEDNPHGNDSAKASRARTKAGDLRDTGIFLDLMHLKKPGGFDISLFYRDIISIAEDEDLRVHFEESSKLEDLLRKVRAKETRKRALSRLKLKLNKDIVISVGIYNLVQKALKPPPIKLYRETNEPVKTKTRTFNTSTGGLLLPSDTKRSQIYGSRQIILEKEETEELKRFDDPGLMLMGFKPLVLLKKHHYLRPSLFVYPEESLVIGSSTLFSALLIKCLEKEVAALCRYTPRRNIPPYFVALVPQEEELDDQKIQVTPPGFQLVFLPFADDKRKMPFTEKIMATPEQVGKMKAIVEKLRFTYRSDSFENPVLQQHFRNLEALALDLMEPEQAVDLTLPKVEAMNKRLGSLVDEFKELVYPPDYNPEGKVTKRKHDNEGSGSKRPKVEYSEEELKTHISKGTLGKFTVPMLKEACRAYGLKSGLKKQELLEALTKHFQD

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

XRCC6-Lys100
Cancer Intensity
BRCA -0.707
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC 0.707
XRCC6-Lys114
Cancer Intensity
BRCA -0.524
COAD
HGSC
ccRCC
GBM
HNSC
LUAD -0.812
LUSC -0.098
non_ccRCC
PDAC
UCEC 1.434
XRCC6-Lys123
Cancer Intensity
BRCA 1.14
COAD
HGSC
ccRCC
GBM -0.408
HNSC
LUAD
LUSC -0.731
non_ccRCC
PDAC
UCEC
XRCC6-Lys129
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM -0.707
HNSC
LUAD
LUSC 0.707
non_ccRCC
PDAC
UCEC
XRCC6-Lys206
Cancer Intensity
BRCA 0.707
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC -0.707
non_ccRCC
PDAC
UCEC
XRCC6-Lys282
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC -0.707
non_ccRCC
PDAC
UCEC 0.707
XRCC6-Lys287
Cancer Intensity
BRCA -1.078
COAD
HGSC
ccRCC
GBM -0.364
HNSC
LUAD 1.558
LUSC -0.425
non_ccRCC
PDAC
UCEC 0.309
XRCC6-Lys31
Cancer Intensity
BRCA 0.526
COAD
HGSC
ccRCC
GBM
HNSC
LUAD -1.492
LUSC 0.356
non_ccRCC
PDAC
UCEC 0.61
XRCC6-Lys317
Cancer Intensity
BRCA 1.102
COAD
HGSC
ccRCC
GBM
HNSC
LUAD -1.313
LUSC -0.033
non_ccRCC
PDAC
UCEC 0.244
XRCC6-Lys331
Cancer Intensity
BRCA -0.542
COAD
HGSC
ccRCC
GBM
HNSC
LUAD 1.237
LUSC -1.031
non_ccRCC
PDAC
UCEC 0.337
XRCC6-Lys338
Cancer Intensity
BRCA -1.668
COAD
HGSC
ccRCC
GBM 0.405
HNSC
LUAD 1.01
LUSC 0.157
non_ccRCC
PDAC
UCEC 0.095
XRCC6-Lys392
Cancer Intensity
BRCA -0.899
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC 1.077
non_ccRCC
PDAC
UCEC -0.178
XRCC6-Lys461
Cancer Intensity
BRCA -1.509
COAD
HGSC
ccRCC
GBM 0.668
HNSC
LUAD 0.727
LUSC -0.553
non_ccRCC
PDAC
UCEC 0.666
XRCC6-Lys463
Cancer Intensity
BRCA -0.707
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC 0.707
non_ccRCC
PDAC
UCEC
XRCC6-Lys516
Cancer Intensity
BRCA -1.335
COAD
HGSC
ccRCC
GBM 1.452
HNSC
LUAD 0.194
LUSC -0.266
non_ccRCC
PDAC
UCEC -0.046
XRCC6-Lys526
Cancer Intensity
BRCA 1.223
COAD
HGSC
ccRCC
GBM -0.791
HNSC
LUAD 0.411
LUSC -0.842
non_ccRCC
PDAC
UCEC
XRCC6-Lys553
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC -0.707
non_ccRCC
PDAC
UCEC 0.707
XRCC6-Lys565
Cancer Intensity
BRCA 1.467
COAD
HGSC
ccRCC
GBM -0.358
HNSC
LUAD 0.22
LUSC -1.292
non_ccRCC
PDAC
UCEC -0.038
XRCC6-Lys570
Cancer Intensity
BRCA 0.707
COAD
HGSC
ccRCC
GBM
HNSC
LUAD -0.707
LUSC
non_ccRCC
PDAC
UCEC
XRCC6-Lys591
Cancer Intensity
BRCA -0.707
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC 0.707
XRCC6-Lys94
Cancer Intensity
BRCA -0.798
COAD
HGSC
ccRCC
GBM
HNSC
LUAD -0.252
LUSC 1.46
non_ccRCC
PDAC
UCEC -0.41

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
- - D Hepatocellular carcinoma Ubiquitination 32775003
- - U Acute leukemia Acetylation 30594243
- - U Neuroblastoma Acetylation 37957138

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: